← FDA DRUG APPROVALS

FDA ANDA · ANDA076059

LISINOPRIL

Sponsor: WATSON LABS

APPLICATION
ANDA076059
TYPE
ANDA
ORIGINAL APPROVAL
2002-07-01
LATEST ACTION
2013-08-14
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

LISINOPRILPrescription
LISINOPRIL 20MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 30MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 10MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 2.5MG · TABLET · ORAL
LISINOPRILPrescription
LISINOPRIL 40MG · TABLET · ORAL

Approval history

2013-08-14Labeling · Supplement 46 · standardAP
2013-02-20Labeling · Supplement 43 · standardAP
2013-02-20Labeling · Supplement 44 · standardAP
2009-01-23Labeling · Supplement 27AP
2008-05-08Labeling · Supplement 25AP
2006-01-19Labeling · Supplement 15AP
2002-07-01OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →